Logo image of ACLX

ARCELLX INC (ACLX) Stock Fundamental Analysis

NASDAQ:ACLX - Nasdaq - US03940C1009 - Common Stock - Currency: USD

70.74  +2.14 (+3.12%)

After market: 70.74 0 (0%)

Fundamental Rating

3

ACLX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. ACLX has a great financial health rating, but its profitability evaluates not so good. ACLX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ACLX has reported negative net income.
ACLX had a negative operating cash flow in the past year.
In the past 5 years ACLX always reported negative net income.
In the past 5 years ACLX reported 4 times negative operating cash flow.
ACLX Yearly Net Income VS EBIT VS OCF VS FCFACLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

Looking at the Return On Assets, with a value of -15.09%, ACLX belongs to the top of the industry, outperforming 83.60% of the companies in the same industry.
Looking at the Return On Equity, with a value of -23.60%, ACLX belongs to the top of the industry, outperforming 83.77% of the companies in the same industry.
Industry RankSector Rank
ROA -15.09%
ROE -23.6%
ROIC N/A
ROA(3y)-27.93%
ROA(5y)-37.97%
ROE(3y)-43.4%
ROE(5y)-50.37%
ROIC(3y)N/A
ROIC(5y)N/A
ACLX Yearly ROA, ROE, ROICACLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

ACLX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACLX Yearly Profit, Operating, Gross MarginsACLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

7

2. Health

2.1 Basic Checks

ACLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACLX has more shares outstanding
The number of shares outstanding for ACLX has been increased compared to 5 years ago.
ACLX has a better debt/assets ratio than last year.
ACLX Yearly Shares OutstandingACLX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ACLX Yearly Total Debt VS Total AssetsACLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ACLX has an Altman-Z score of 8.43. This indicates that ACLX is financially healthy and has little risk of bankruptcy at the moment.
ACLX's Altman-Z score of 8.43 is amongst the best of the industry. ACLX outperforms 86.39% of its industry peers.
There is no outstanding debt for ACLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.43
ROIC/WACCN/A
WACC9.19%
ACLX Yearly LT Debt VS Equity VS FCFACLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 4.78 indicates that ACLX has no problem at all paying its short term obligations.
ACLX has a Current ratio of 4.78. This is comparable to the rest of the industry: ACLX outperforms 52.71% of its industry peers.
ACLX has a Quick Ratio of 4.78. This indicates that ACLX is financially healthy and has no problem in meeting its short term obligations.
ACLX has a Quick ratio (4.78) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.78
Quick Ratio 4.78
ACLX Yearly Current Assets VS Current LiabilitesACLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

ACLX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -34.38%.
The Revenue has decreased by -2.16% in the past year.
EPS 1Y (TTM)-34.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-314.27%
Revenue 1Y (TTM)-2.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-75.83%

3.2 Future

ACLX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.24% yearly.
The Revenue is expected to grow by 42.82% on average over the next years. This is a very strong growth
EPS Next Y-41.55%
EPS Next 2Y-30.21%
EPS Next 3Y-21.88%
EPS Next 5Y25.24%
Revenue Next Year-25.43%
Revenue Next 2Y23.29%
Revenue Next 3Y28.3%
Revenue Next 5Y42.82%

3.3 Evolution

ACLX Yearly Revenue VS EstimatesACLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
ACLX Yearly EPS VS EstimatesACLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACLX Price Earnings VS Forward Price EarningsACLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACLX Per share dataACLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

ACLX's earnings are expected to decrease with -21.88% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.21%
EPS Next 3Y-21.88%

More info and screens

0

5. Dividend

5.1 Amount

ACLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCELLX INC

NASDAQ:ACLX (3/7/2025, 8:03:24 PM)

After market: 70.74 0 (0%)

70.74

+2.14 (+3.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-20 2025-03-20/amc
Inst Owners102.94%
Inst Owner Change17.29%
Ins Owners0.69%
Ins Owner Change4.37%
Market Cap3.89B
Analysts85.6
Price Target118.7 (67.8%)
Short Float %16.79%
Short Ratio11.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-34.09%
Min Revenue beat(2)-42.43%
Max Revenue beat(2)-25.74%
Revenue beat(4)2
Avg Revenue beat(4)10.35%
Min Revenue beat(4)-42.43%
Max Revenue beat(4)86.18%
Revenue beat(8)3
Avg Revenue beat(8)22.51%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.61%
EPS NY rev (1m)0%
EPS NY rev (3m)6.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.19%
Revenue NY rev (1m)-23.32%
Revenue NY rev (3m)-16.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 36.01
P/FCF N/A
P/OCF N/A
P/B 8.55
P/tB 8.55
EV/EBITDA N/A
EPS(TTM)-1.99
EYN/A
EPS(NY)-2.33
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS1.96
BVpS8.28
TBVpS8.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.09%
ROE -23.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.93%
ROA(5y)-37.97%
ROE(3y)-43.4%
ROE(5y)-50.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 258.94%
Cap/Sales 12.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.78
Quick Ratio 4.78
Altman-Z 8.43
F-Score3
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)494.02%
Cap/Depr(5y)435.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-314.27%
EPS Next Y-41.55%
EPS Next 2Y-30.21%
EPS Next 3Y-21.88%
EPS Next 5Y25.24%
Revenue 1Y (TTM)-2.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-75.83%
Revenue Next Year-25.43%
Revenue Next 2Y23.29%
Revenue Next 3Y28.3%
Revenue Next 5Y42.82%
EBIT growth 1Y-53.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.95%
EBIT Next 3Y-6.82%
EBIT Next 5Y33.74%
FCF growth 1Y-152.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-140.21%
OCF growth 3YN/A
OCF growth 5YN/A